Endologix Inc (ELGX) 14.51 $ELGX
Endologix to Report Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015
GlobeNewswire - Mon Jan 26, 9:04AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2014 financial results, which will take place on Wednesday, February 25, 2015 after the close of the market.
ELGX: 14.51 (+0.21)
Endologix reports February 25
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 8:57AM CST
ELGX: 14.51 (+0.21)
Downgrade Alert for Endologix (ELGX)
Comtex SmarTrend(R) - Thu Jan 08, 8:05AM CST
Endologix (NASDAQ:ELGX) was downgraded from Buy to Neutral at BTIG today. The stock closed yesterday at $15.16 on volume of 864,000 shares, above average daily volume of 556,000. Endologix, Inc. develops, manufactures, sells, and markets minimally invasive treatments for vascular diseases. The Company's products include the Powerlink System, a catheter-based endoluminal stent graft that treats abdominal aortic aneurysms. Endologix's products are sold in the United States as well as international markets.
ELGX: 14.51 (+0.21)
Endologix to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 05, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, is scheduled to present at the 33 Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
JPM: 59.67 (+0.10), ELGX: 14.51 (+0.21)
Uptrend Call Working As Endologix Stock Rises 15.7% (ELGX)
Comtex SmarTrend(R) - Tue Dec 30, 11:25AM CST
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on December 9th, 2014 at $13.60. In approximately 3 weeks, Endologix has returned 15.70% as of today's recent price of $15.73.
ELGX: 14.51 (+0.21)
Can The Uptrend Continue for Endologix (ELGX)?
Endologix to Report Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015
GlobeNewswire - Mon Jan 26, 9:04AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2014 financial results, which will take place on Wednesday, February 25, 2015 after the close of the market.
ELGX: 14.51 (+0.21)
Endologix reports February 25
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 8:57AM CST
ELGX: 14.51 (+0.21)
Downgrade Alert for Endologix (ELGX)
Comtex SmarTrend(R) - Thu Jan 08, 8:05AM CST
Endologix (NASDAQ:ELGX) was downgraded from Buy to Neutral at BTIG today. The stock closed yesterday at $15.16 on volume of 864,000 shares, above average daily volume of 556,000. Endologix, Inc. develops, manufactures, sells, and markets minimally invasive treatments for vascular diseases. The Company's products include the Powerlink System, a catheter-based endoluminal stent graft that treats abdominal aortic aneurysms. Endologix's products are sold in the United States as well as international markets.
ELGX: 14.51 (+0.21)
Endologix to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 05, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, is scheduled to present at the 33 Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
JPM: 59.67 (+0.10), ELGX: 14.51 (+0.21)
Uptrend Call Working As Endologix Stock Rises 15.7% (ELGX)
Comtex SmarTrend(R) - Tue Dec 30, 11:25AM CST
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on December 9th, 2014 at $13.60. In approximately 3 weeks, Endologix has returned 15.70% as of today's recent price of $15.73.
ELGX: 14.51 (+0.21)
Can The Uptrend Continue for Endologix (ELGX)?
